ReviewJSES international2025
Which is the optimal treatment and the most significant prognostic factor for reverse shoulder arthroplasty in case of PHAROS 2 humeral bone loss? A proportional meta-analysis of nononcologic patients.
Review in JSES international, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Does surgical indication influence implant survival in reverse shoulder arthroplasty? A comparative cohort study of fracture and glenohumeral osteoarthritis.European journal of orthopaedic surgery & traumatology : orthopedie traumatologie · 2026Article
- A Comprehensive Review of 3D Imaging and Printing in Proximal Humerus Fractures and Sequelae.Journal of clinical medicine · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Reverse total shoulder arthroplasty (rTSA) for proximal humerus bone loss is linked with increased risks of complications and reoperation. This study aimed to compare the complication and reoperation rates between patients with unaddressed humeral defect (control group [CG]) and those receiving proximal humerus allograft prosthesis composite (APC) or mega-prosthesis (MP) (study group [SG]). Methods: Systematic searches were conducted in MEDLINE/PubMed, Web of Science, and Embase to find studies on rTSA outcomes in proximal humerus bone loss cases. Search terms included boolean combinations of "proximal humerus bone loss," "revision shoulder replacement," "arthroplasty," "prosthesis," and "reconstruction." Studies with <24 months follow-up, humeral defects over 7 cm or under 3 cm, case reports, and oncologic resections were excluded. Study design, demographic data, surgical methods, and outcomes were extracted and analyzed. A proportional meta-analysis compared complication and reoperation rates between CG and SG, with subgroup analyses for APC and MP. Multivariate logistic regression identified predictive prognostic factors, using the modified Coleman Methodology Score for bias risk assessment. Results: Thirteen studies were included; seven (167 cases) in CG, four (113 cases) in SG treated with APC, and two (51 cases) with MP. The two groups were comparable in modified Coleman Methodology Score, age, sex, medium follow-up, preoperative visual analog scale, elevation, number of previous surgeries, medium bone loss, and preoperative diagnosis. No significant differences were found in complication and reoperation rates between CG and SG or between APC and MP groups ( Conclusion: Using APC or MP during rTSA in case of Proximal Humeral Arthroplasty Revision Osseous inSufficiency (PHAROS) 2 bone loss is neither associated with a lower complication and reoperation rate nor with better postoperative pain or elevation. Patients affected by preoperative infection are at higher risk of developing symptomatic complications and suffer reoperation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.